We believe that JNT-517 offers a differentiated approach to PKU with an oral small molecule that can be used to treat any PKU patient, notwithstanding age or PAH mutation,” said Joel Barrish, Ph ...

Treatment with JNT-517 demonstrated a statistically significant mean blood phenylalanine reduction of 51% versus baseline JNT-517 was safe and well tolerated with no serious adverse events Jnana ...